Food and Drug Administration (FDA) has issued an alert about the potential risks of using unapproved versions of glucagon-like peptide-1 (GLP-1) receptor agonist drugs for weight loss. In addition, the agency recommends that health care providers exercise caution when establishing appropriate doses, titration, and dosing schedules for patients taking compounded semaglutide and tirzepatide products. Individuals are encouraged to report any adverse events or problems with GLP-1 medications to FDA’s MedWatch Adverse Event Reporting Program.